Minimising Mortality from Alcoholic Hepatitis

The MRC Stratified Medicine application entitled ‘Minimising Mortality from Alcoholic Hepatitis’ will commence in April 2018 and will last for 5 years. The award was for £5M and will involve Imperial College (Mark Thursz, Harry Antonaides, Elaine Holmes), University of Birmingham (David Adams, Trish Lalor, Chris Weston), University College London (William Rosenberg), MRC Biostatistics Unit Cambridge (Paul Newcombe), University of Edinburgh (Stuart Forbes) and University of Plymouth (Ashwin Dhanda) as well as the 40 clinical sites recruiting patients.

Read more on the BSG website > here.

Researchers awarded £2.3m grant for clinical trial on patients with liver cirrhosis and oesophageal varices

Clinical researchers at University of Birmingham, in collaboration with University of Edinburgh, University of Leeds and the Royal Liverpool Hospital to lead a NIHR (National Institute of Health Research) funded multicentre clinical trial to research CALIBRE - Carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis.

Read more on the BSG website > here.

Receipt of Curative Resection or Palliative Care for Hepato-pancreatico-biliary tumours

Pancreatic adenocarcinoma is a leading cause of cancer death in the UK. 80% of patients with pancreatic cancer present with unresectable disease. There is considerable regional variation in the diagnostic pathway for patients with pancreatic and other peri-ampullary cancers, and differing strategies for the management of malignant biliary obstruction.

The aim of this study is to map the management pathway including investigations, biliary decompression and surgery from presentation to 90-day outcome for patients with pancreatic or peri-ampullary cancers as well as those with malignant biliary obstruction.

Read more on the BSG website > here.

Now recruiting: Trial of Faecal Microbiota Transplantation (FMT) in Cirrhosis (PROFIT-01)

The primary objective of this study will be to assess whether stabilising gut dysbiosis with FMT in patients with advanced cirrhosis is both feasible and safe. 

Read more on the BSG website > here